Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 10/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15851052 | 0.93 | KMT2A (0.44) | HTTMEN1KMT2A | |
| SCHEMBL17286730 | 0.93 | ATM (0.43) | HTTMRGPRX4TSHRRXRARXRB | |
| SCHEMBL17804508 | 0.92 | MAPT (0.40) | HTTMRGPRX4TSHRPPARARXRA | |
| SCHEMBL16911478 | 0.92 | SMN1; SMN2 (0.43) | HTTMRGPRX4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16549498 | 0.91 | MRGPRX4 (0.45) | HTTMRGPRX4PPARARXRARXRB | |
| SCHEMBL16911399 | 0.91 | TAS1R3 (0.36) | HTTMRGPRX4MEN1KMT2A | |
| SCHEMBL16442754 | 0.91 | HPGDS (0.40) | HTT | |
| SCHEMBL16442895 | 0.90 | KMT2A (0.35) | HTTMRGPRX4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15851193 | 0.89 | TNKS (0.40) | HTTMRGPRX4MEN1KMT2A | |
| SCHEMBL15851069 | 0.89 | ATP4A (0.40) | HTTMRGPRX4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3040332-B1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL CO (JP) | 2020-06-03 | — | — | EP | disclosed |
| EP-3040332-B1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL CO (JP) | 2020-06-03 | — | — | EP | disclosed |
| EP-3029030-B1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | SUMITOMO CHEMICAL CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3029030-B1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | SUMITOMO CHEMICAL CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-9730448-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9730448-B2 | Tetrazolinone compound and use of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9512090-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9512090-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20160205935-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040332-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | Sumitomo Chemical Company, Limited (JP) | 2016-07-06 | — | — | EP | disclosed |
| EP-3040332-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | Sumitomo Chemical Company, Limited (JP) | 2016-07-06 | — | — | EP | disclosed |
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029030-A1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| EP-3029030-A1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015030217-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | 住友化学株式会社 (JP) | 2015-03-05 | — | — | WO | disclosed |
| WO-2015016373-A1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | 住友化学株式会社 (JP) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | CYP1A1, CASP1, TCOF1 | HTT 1597/4885MRGPRX4 1910/4885TSHR 51/4885 |
| US-20160205935-A1 | TETRAZOLINONE COMPOUND AND USE OF SAME | MT-CO1, UQCRB, RPS20 | HTT 2540/4885MRGPRX4 1829/4885TSHR 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.